Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 3 , Pages 585-609 , September 2008

The immunocompromised adult patient and surgery

  • Keith E. Littlewood, MD (Vice-Chair, Education)

      Affiliations

    • Corresponding Author InformationTel.: +1 434 924 9509; Fax: +1 434 982 0019.

References 

  1. Nieuwkerk PT, Hillebrand-Haverkort ME, Vriesendorp R, et al. Quality of life after starting highly active antiretroviral therapy for chronic HIV-1 infection at different CD4 cell counts. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2007;45(5):600–601
  2. van Sighem AI, van de Wiel MA, Ghani AC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. [see comment] AIDS. 2003;17(15):2227–2236
  3. Hariri S, McKenna MT. Epidemiology of human immunodeficiency virus in the United States. Clinical Microbiology Reviews. 2007;20(3):478–488
  4. Tapper ML, Daar ES, Piliero PJ, et al. Strategies for initiating combination antiretroviral therapy. Aids Patient Care STDS. 2005;19(4):224–238
  5. Hofman P, Nelson AM. The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update. Current Medicinal Chemistry. 2006;13(26):3121–3132
  6. Corti M, Villafane MF, Ambroggi M, et al. Soft tissue abscess and lymphadenitis due to Mycobacterium avium complex as an expression of immune reconstitution inflammatory syndrome after a second scheme of highly active antiretroviral therapy. Revista do Instituto de Medicina Tropical de Sao Paulo. 2007;49(4):267–270
  7. Pignataro P, Rocha Ada S, Nery JA, et al. Leprosy and AIDS: two cases of increasing inflammatory reactions at the start of highly active antiretroviral therapy. European Journal of Clinical Microbiology & Infectious Diseases. 2004;23(5):408–411
  8. Morris DG, Jasmer RM, Huang L, et al. Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Chest. 2003;124(3):929–935
  9. French MA, Lewin SR, Dykstra C, et al. Graves' disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction. AIDS Research and Human Retroviruses. 2004;20(2):157–162
  10. Miralles P, Berenguer J, Lacruz C, et al. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS. 2001;15(14):1900–1902
  11. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmunity Reviews. 2002;1(6):329–337
  12. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clinical Infectious Diseases. 2003;36(4):482–490
  13. Luther J, Glesby MJ. Dermatologic adverse effects of antiretroviral therapy: recognition and management. American Journal of Clinical Dermatology. 2007;8(4):221–233
  14. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nature Reviews Drug Discovery. 2003;2(8):624–634
  15. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2002;31(3):257–275
  16. Geddes R, Knight S, Moosa MY, et al. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. South African Medical Journal Suid-Afrikaanse Tydskrif Vir Geneeskunde. 2006;96(8):722–724
  17. Wester CW, Okezie OA, Thomas AM, et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2007;46(3):318–322
  18. Stankov MV, Behrens GM. HIV-therapy associated lipodystrophy: experimental and clinical evidence for the pathogenesis and treatment. Endocrine, Metabolic & Immune Disorders Drug Targets. 2007;7(4):237–249
  19. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. Journal of Neurovirology. 2002;8(Suppl 2):115–121
  20. Powderly WG. Long-term exposure to lifelong therapies. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2002;29(Suppl 1):S28–S40
  21. Lewis W. Cardiomyopathy in AIDS: a pathophysiological perspective. Progress in Cardiovascular Diseases. 2000;43(2):151–170
  22. Lewis W, Haase CP, Raidel SM, et al. Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. Laboratory Investigation. 2001;81(11):1527–1536
  23. Milinkovic A, Martinez E. Current perspectives on HIV-associated lipodystrophy syndrome. The Journal of Antimicrobial Chemotherapy. 2005;56(1):6–9
  24. Florescu D, Kotler DP. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antiviral Therapy. 2007;12(2):149–162
  25. Balasubramanyam A, Sekhar RV, Jahoor F, et al. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of ‘systemic steatosis’. Current Opinion in Lipidology. 2004;15(1):59–67
  26. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Journal of Hepatology. 2006;44(1 Suppl):S132–S139
  27. de Silva TI, Post FA, Griffin MD, et al. HIV-1 infection and the kidney: an evolving challenge in HIV medicine. Mayo Clinic Proceedings. 2007;82(9):1103–1116
  28. Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrology Dialysis Transplantation. 2006;21(10):2809–2813
  29. Reveille JD, Williams FM. Infection and musculoskeletal conditions: rheumatologic complications of HIV infection. Best Practice & Research in Clinical Rheumatology. 2006;20(6):1159–1179
  30. Moyle G. Anaemia in persons with HIV infection: prognostic marker and contributor to morbidity. AIDS Reviews. 2002;4(1):13–20
  31. Lundy J. Anesthesia and surgery: a double-edged sword for the cancer patient. Journal of Surgical Oncology. 1980;14(1):61–65
  32. Weesner KM, Bledsoe M, Chauvenet A, et al. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer. 1991;68(2):435–438
  33. Thorne AC, Orazem JP, Shah NK, et al. Isoflurane versus fentanyl: hemodynamic effects in cancer patients treated with anthracyclines. Journal of Cardiothoracic and Vascular Anesthesia. 1993;7(3):307–311
  34. Burrows FA, Hickey PR, Colan S. Perioperative complications in patients with anthracycline chemotherapeutic agents. Canadian Anaesthetists' Society Journal. 1985;32(2):149–157
  35. Gorton H, Wilson R, Robinson A, et al. Survivors of childhood cancers: implications for obstetric anaesthesia. British Journal of Anaesthesia. 2000;85(6):911–913
  36. Zaniboni A, Prabhu S, Audisio RA. Chemotherapy and anaesthetic drugs: too little is known. Lancet Oncology. 2005;6(3):176–181
  37. Chabner BA, Amrein PC, Druker BJ, et al. Antineoplastic agents. In:  Brunton LL,  Lazo JS,  Parker KL editor. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill, Inc; 2006;p. Chapter 51
  38. Andreyev HJ. Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. Clinical Oncology (Royal College of Radiologists (Great Britain)). 2007;19(10):790–799
  39. Kong FM, Pan C, Eisbruch A, et al. Physical models and simpler dosimetric descriptors of radiation late toxicity. Seminars in Radiation Oncology. 2007;17(2):108–120
  40. Wang J, Boerma M, Fu Q, et al. Significance of endothelial dysfunction in the pathogenesis of early and delayed radiation enteropathy. [see comment] World Journal of Gastroenterology. 2007;13(22):3047–3055
  41. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clinical Cancer Research. 2008;14(1):14–24
  42. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. [see comment] Journal of Clinical Oncology. 2007;25(25):3991–4008
  43. Ghafoori P, Marks LB, Vujaskovic Z, et al. Radiation-induced lung injury. Assessment, management, and prevention. Oncology (Williston Park). 2008;22(1):37–47[discussion: 52–3]
  44. Madani I, De Ruyck K, Goeminne H, et al. Predicting risk of radiation-induced lung injury. Journal of Thoracic Oncology. 2007;2(9):864–874
  45. Goldiner PL, Carlon GC, Cvitkovic E, et al. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. British Medical Journal. 1978;1(6128):1664–1667
  46. LaMantia KR, Glick JH, Marshall BE. Supplemental oxygen does not cause respiratory failure in bleomycin-treated surgical patients. Anesthesiology. 1984;60(1):65–67
  47. Matalon S, Harper WV, Nickerson PA, et al. Intravenous bleomycin does not alter the toxic effects of hyperoxia in rabbits. Anesthesiology. 1986;64(5):614–619
  48. Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?. The Journal of Urology. 1998;160(4):1347–1352
  49. Hopf HW, Rollins MD. Wounds: an overview of the role of oxygen. Antioxidants & Redox Signaling. 2007;9(8):1183–1192
  50. Panjrath GS, Jain D. Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging. Journal of Nuclear Cardiology. 2006;13(3):415–426
  51. Xin YF, Zhou GL, Deng ZY, et al. Protective effect of Lycium barbarum on doxorubicin-induced cardiotoxicity. Phytotherapy Research: PTR. 2007;21(11):1020–1024
  52. Outomuro D, Grana DR, Azzato F, et al. Adriamycin-induced myocardial toxicity: new solutions for an old problem?. International Journal of Cardiology. 2007;117(1):6–15
  53. Kelishomi RB, Ejtemaeemehr S, Tavangar SM, et al. Morphine is protective against doxorubicin-induced cardiotoxicity in rat. Toxicology. 2008;243(1–2):96–104
  54. Morandi P, Ruffini PA, Benvenuto GM, et al. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplantation. 2005;35(4):323–334
  55. Berliner S, Rahima M, Sidi Y, et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Investigation. 1990;8(6):583–586
  56. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. Journal of Clinical Oncology. 2000;18(8):1725–1732
  57. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. European Journal of Heart Failure. 2002;4(3):235–242
  58. Alter P, Herzum M, Soufi M, et al. Cardiotoxicity of 5-fluorouracil. Cardiovascular & Hematological Agents in Medicinal Chemistry. 2006;4(1):1–5
  59. Perik PJ, de Korte MA, van Veldhuisen DJ, et al. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Review of Anticancer Therapy. 2007;7(12):1763–1771
  60. Telli ML, Hunt SA, Carlson RW, et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. Journal of Clinical Oncology. 2007;25(23):3525–3533
  61. Mitchell MS. Combinations of anticancer drugs and immunotherapy. Cancer Immunology, Immunotherapy: CII. 2003;52(11):686–692
  62. Au WY, Kwong YL. Arsenic trioxide: safety issues and their management. Acta Pharmacologica Sinica. 2008;29(3):296–304
  63. Owczuk R, Wujtewicz MA, Sawicka W, et al. Is prolongation of the QTc interval during isoflurane anaesthesia more prominent in women pretreated with anthracyclines for breast cancer?. British Journal of Anaesthesia. 2004;92(5):658–661
  64. Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of chemotherapy. Seminars in Oncology. 2006;33(1):50–67
  65. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist. 2001;6(2):162–176
  66. Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clinical Chemistry. 1996;42(8 Pt 2):1322–1329
  67. Delaney P. Vincristine-induced laryngeal nerve paralysis. Neurology. 1982;32(11):1285–1288
  68. Annino DJ, MacArthur CJ, Friedman EM. Vincristine-induced recurrent laryngeal nerve paralysis. Laryngoscope. 1992;102(11):1260–1262
  69. Burns BV, Shotton JC. Vocal fold palsy following vinca alkaloid treatment. The Journal of Laryngology and Otology. 1998;112(5):485–487
  70. Ryan SP, DelPrete SA, Weinstein PW, et al. Low-dose vincristine-associated bilateral vocal cord paralysis. Connecticut Medicine. 1999;63(10):583–584
  71. Harris CM, Blanchaert RH. Bilateral recurrent laryngeal nerve palsy resulting from treatment with vincristine. Journal of Oral and Maxillofacial Surgery. 2006;64(4):738–739
  72. Praveen CV, De Lord CF. Bilateral vocal fold paralysis following treatment with vincristine. The Journal of Laryngology and Otology. 2006;120(5):423
  73. Rezvani K, Bain BJ, Coulter CA. Loss of singing ability caused by vincristine. Clinical and Laboratory Haematology. 1998;20(1):47–48
  74. von Schlippe M, Fowler CJ, Harland SJ. Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. British Journal of Cancer. 2001;85(6):823–826
  75. Hebl JR, Horlocker TT, Pritchard DJ. Diffuse brachial plexopathy after interscalene blockade in a patient receiving cisplatin chemotherapy: the pharmacologic double crush syndrome. Anesthesia and Analgesia. 2001;92(1):249–251
  76. 2007 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997–2006. Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD. In, <http://www.optn.org/data/annualReport.asp>
  77. Toledo-Pereyra LH, Toledo AH. 1954. Journal of Investigative Surgery. 2005;18(6):285–290
  78. Atala A, Bauer SB, Soker S, et al. Tissue-engineered autologous bladders for patients needing cystoplasty. [see comment] Lancet. 2006;367(9518):1241–1246
  79. Cullen DK, Stabenfeldt SE, Simon CM, et al. In vitro neural injury model for optimization of tissue-engineered constructs. Journal of Neuroscience Research. 2007;85(16):3642–3651
  80. Petersen MC, Lazar J, Jacob HJ, et al. Tissue engineering: a new frontier in physiological genomics. Physiological Genomics. 2007;32(1):28–32
  81. Huang JH, Zager EL, Zhang J, et al. Harvested human neurons engineered as live nervous tissue constructs: implications for transplantation. Laboratory investigation. Journal of Neurosurgery. 2008;108(2):343–347
  82. Gunthart M, Kearns-Jonker M. Gene therapy for the induction of chimerism and transplant tolerance. Current Gene Therapy. 2007;7(6):411–420
  83. Miao CH. Recent advances in immune modulation. Current Gene Therapy. 2007;7(5):391–402
  84. Thompson C, Neal M, Peters N. Importance of transplantation history in ABO discrepancies. Clinical Laboratory Science. 2005;18(1):5–7
  85. Pelletier SJ, Crabtree TD, Gleason TG, et al. Characteristics of infectious complications associated with mortality after solid organ transplantation. Clinical Transplantation. 2000;14(4 Pt 2):401–408
  86. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. American Journal of Transplantation. 2004;4(3):384–389
  87. Freund M, Kleine HD. The role of GM-CSF in infection. Infection. 1992;20(Suppl 2):S84–S92
  88. Meropol NJ, Wood DE, Nemunaitis J, et al. Randomized, placebo-controlled, multicenter trial of granulocyte-macrophage colony-stimulating factor as infection prophylaxis in oncologic surgery. Leukine Surgical Prophylaxis Research Group. Journal of Clinical Oncology. 1998;16(3):1167–1173
  89. Oosterling SJ, Mels AK, Geijtenbeek TB, et al. Preoperative granulocyte/macrophage colony-stimulating factor (GM-CSF) increases hepatic dendritic cell numbers and clustering with lymphocytes in colorectal cancer patients. Immunobiology. 2006;211(6–8):641–649
  90. Kirman I, Belizon A, Balik E, et al. Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery. European Journal of Surgical Oncology. 2007;33(10):1169–1176
  91. Mannick JA, Rodrick ML, Lederer JA. The immunologic response to injury. [see comment] Journal of the American College of Surgeons. 2001;193(3):237–244
  92. Puig NR, Ferrero P, Bay ML, et al. Effects of sevoflurane general anesthesia: immunological studies in mice. International Immunopharmacology. 2002;2(1):95–104
  93. Elena G, Amerio N, Ferrero P, et al. Effects of repetitive sevoflurane anaesthesia on immune response, select biochemical parameters and organ histology in mice. Laboratory Animals. 2003;37(3):193–203
  94. Inada T, Yamanouchi Y, Jomura S, et al. Effect of propofol and isoflurane anaesthesia on the immune response to surgery. Anaesthesia. 2004;59(10):954–959
  95. Chen HI, Hsieh NK, Kao SJ, et al. Protective effects of propofol on acute lung injury induced by oleic acid in conscious rats. Critical Care Medicine. 2008;36(4):1214–1221
  96. Marik PE. Propofol: an immunomodulating agent. Pharmacotherapy. 2005;25(5 Pt 2):28S–33S
  97. Herr DL, Kelly K, Hall JB, et al. Safety and efficacy of propofol with EDTA when used for sedation of surgical intensive care unit patients. Intensive Care Medicine. 2000;26(Suppl 4):S452–S462
  98. Fuentes JM, Talamini MA, Fulton WB, et al. General anesthesia delays the inflammatory response and increases survival for mice with endotoxic shock. Clinical & Vaccine Immunology: CVI. 2006;13(2):281–288
  99. Beilin B, Rusabrov Y, Shapira Y, et al. Low-dose ketamine affects immune responses in humans during the early postoperative period. British Journal of Anaesthesia. 2007;99(4):522–527
  100. Swanton BJ, Shorten GD. Anti-inflammatory effects of local anesthetic agents. International Anesthesiology Clinics. 2003;41(1):1–19
  101. Lahat A, Horin SB, Lang A, et al. Lidocaine down-regulates nuclear factor-kappaB signalling and inhibits cytokine production and T cell proliferation. Clinical and Experimental Immunology. 2008;152(2):320–327
  102. Delogu G, Moretti S, Antonucci A, et al. Apoptogenic effect of fentanyl on freshly isolated peripheral blood lymphocytes. Journal of Trauma-Injury Infection & Critical Care. 2004;57(1):75–81
  103. Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain. 2004;110(1–2):385–392
  104. Sacerdote P. Opioids and the immune system. Palliative Medicine. 2006;20(Suppl 1):s9–s15
  105. Yeager MP, Procopio MA, DeLeo JA, et al. Intravenous fentanyl increases natural killer cell cytotoxicity and circulating CD16(+) lymphocytes in humans. Anesthesia and Analgesia. 2002;94(1):94–99
  106. Sharp BM. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behavior and Immunity. 2006;20(1):9–14
  107. Angele MK, Faist E. Clinical review: immunodepression in the surgical patient and increased susceptibility to infection. [see comment] Critical Care. 2002;6(4):298–305
  108. Vallejo R, Hord ED, Barna SA, et al. Perioperative immunosuppression in cancer patients. Journal of Environmental Pathology, Toxicology and Oncology. 2003;22(2):139–146
  109. Kehlet H. Manipulation of the metabolic response in clinical practice. World Journal of Surgery. 2000;24(6):690–695
  110. de Leon-Casasola OA. Immunomodulation and epidural anesthesia and analgesia. Regional Anesthesia. 1996;21(6 Suppl):24–25
  111. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990–1999. [see comment] Anesthesiology. 2004;101(4):950–959
  112. Wang LP, Hauerberg J, Schmidt JF. Incidence of spinal epidural abscess after epidural analgesia: a national 1-year survey. Anesthesiology. 1999;91(6):1928–1936
  113. Wada H, Seki S, Takahashi T, et al. Combined spinal and general anesthesia attenuates liver metastasis by preserving TH1/TH2 cytokine balance. Anesthesiology. 2007;106(3):499–506
  114. Ciepichal J, Kubler A. Effect of general and regional anesthesia on some neutrophil functions. Archivum Immunologiae et Therapiae Experimentalis. 1998;46(3):183–192
  115. Le Cras AE, Galley HF, Webster NR. Spinal but not general anesthesia increases the ratio of T helper 1 to T helper 2 cell subsets in patients undergoing transurethral resection of the prostate. Anesthesia and Analgesia. 1998;87(6):1421–1425
  116. Kawasaki T, Ogata M, Kawasaki C, et al. Effects of epidural anaesthesia on surgical stress-induced immunosuppression during upper abdominal surgery. [see comment] British Journal of Anaesthesia. 2007;98(2):196–203
  117. Walker WS, Codispoti M, Soon SY, et al. Long-term outcomes following VATS lobectomy for non-small cell bronchogenic carcinoma. European Journal of Cardio-thoracic Surgery. 2003;23(3):397–402
  118. Roviaro G, Varoli F, Vergani C, et al. Long-term survival after videothoracoscopic lobectomy for stage I lung cancer. Chest. 2004;126(3):725–732
  119. Sebastien R, Marie-Christine E, Vincent B, et al. Laparoscope use and surgical site infections in digestive surgery. Annals of Surgery. 2008;247(4):627–632
  120. Sekhar N, Torquati A, Youssef Y, et al. A comparison of 399 open and 568 laparoscopic gastric bypasses performed during a 4-year period. Surgical Endoscopy. 2007;21(4):665–668
  121. Hinojosa MW, Murrell ZA, Konyalian VR, et al. Comparison of laparoscopic vs open sigmoid colectomy for benign and malignant disease at academic medical centers. Journal of Gastrointestinal Surgery. 2007;11(11):1423–1429[discussion: 1429–30]
  122. Pokala N, Sadhasivam S, Kiran RP, et al. Complicated appendicitis–is the laparoscopic approach appropriate? A comparative study with the open approach: outcome in a community hospital setting. The American Surgeon. 2007;73(8):737–741[discussion: 741–2]
  123. Sauerland S, Lefering R, Neugebauer EAM. Laparoscopic versus open surgery for suspected appendicitis. Cochrane Database of Systematic Reviews. 2004;18(4):CD001546
  124. Whitson BA, D'Cunha J, Maddaus MA. Minimally invasive cancer surgery improves patient survival rates through less perioperative immunosuppression. Medical Hypotheses. 2007;68(6):1328–1332
  125. Fortis C, Ferrero E, Biffi M, et al. Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation. Cancer Immunology, Immunotherapy: CII. 1991;33(2):128–132
  126. von Rohr A, Ghosh AK, Thatcher N, et al. Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. British Journal of Cancer. 1993;67(1):163–171
  127. Aulitzky WE, Schuler M, Peschel C, et al. Interleukins. Clinical pharmacology and therapeutic use. Drugs. 1994;48(5):667–677
  128. Angevin E, Valteau-Couanet D, Farace F, et al. Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer. Journal of Immunotherapy with Emphasis on Tumor Immunology. 1995;18(3):188–195
  129. Klatte T, Ittenson A, Rohl FW, et al. Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial. British Journal of Cancer. 2006;95(9):1167–1173
  130. Mitchison NA. Blood transfusion in fowl: an example of immunological tolerance requiring the persistence of antigen. Bulletin de la Société Internationale de Chirurgie. 1959;18(3):257–273
  131. Halasz NA, Orloff MJ. Antigen pretreatment and mechanisms of the resulting temporary tolerance. Proceedings of the Society for Experimental Biology and Medicine. 1964;116:987–990
  132. Danielson CF, Filo RS, O'Donnell JA, et al. Institutional variation in hemotherapy for solid organ transplantation. [erratum appears in Transfusion 1996 Aug;36(8):764] Transfusion (Paris). 1996;36(3):263–267
  133. Chen G, Zhang FJ, Gong M, et al. Effect of perioperative autologous versus allogeneic blood transfusion on the immune system in gastric cancer patients. Journal of Zhejiang University. Science. B. 2007;8(8):560–565
  134. Carter JJ, Whelan RL. The immunologic consequences of laparoscopy in oncology. Surgical Oncology Clinics of North America. 2001;10(3):655–677
  135. Wildbrett P, Oh A, Carter JJ, et al. Increased rates of pulmonary metastases following sham laparotomy compared to CO2 pneumoperitoneum and the inhibition of metastases utilizing perioperative immunomodulation and a tumor vaccine. Surgical Endoscopy. 2002;16(8):1162–1169
  136. Carter JJ, Feingold DL, Oh A, et al. Perioperative immunomodulation with Flt3 kinase ligand or a whole tumor cell vaccine is associated with a reduction in lung metastasis formation after laparotomy in mice. Surgical Innovation. 2006;13(1):41–47
  137. Bohm M, Ittenson A, Philipp C, et al. Complex perioperative immuno-dysfunction in patients with renal cell carcinoma. The Journal of Urology. 2001;166(3):831–836
  138. Schinkel C, Licht K, Zedler S, et al. Perioperative treatment with human recombinant interferon-gamma: a randomized double-blind clinical trial. Shock. 2001;16(5):329–333
  139. Enesel MB, Acalovschi I, Grosu V, et al. Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients. Anticancer Research. 2005;25(6C):4583–4590
  140. Oosterling SJ, van der Bij GJ, Mels AK, et al. Perioperative IFN-alpha to avoid surgically induced immune suppression in colorectal cancer patients. Histology and Histopathology. 2006;21(7):753–760
  141. Licht AK, Schinkel C, Zedler S, et al. Effects of perioperative recombinant human IFN-gamma (rHuIFN-gamma) application in vivo on T cell response. Journal of Interferon & Cytokine Research. 2003;23(3):149–154
  142. Weiss G, Meyer F, Matthies B, et al. Immunomodulation by perioperative administration of n-3 fatty acids. The British Journal of Nutrition. 2002;87(Suppl 1):S89–S94
  143. Exner R, Tamandl D, Goetzinger P, et al. Perioperative GLY-GLN infusion diminishes the surgery-induced period of immunosuppression: accelerated restoration of the lipopolysaccharide-stimulated tumor necrosis factor-alpha response. Annals of Surgery. 2003;237(1):110–115
  144. Isaacs JD. T cell immunomodulation–the Holy Grail of therapeutic tolerance. Current Opinion in Pharmacology. 2007;7(4):418–425
  145. Perkins BA, Bril V. Emerging therapies for diabetic neuropathy: a clinical overview. Current Diabetes Reviews. 2005;1(3):271–280
  146. Pollard LC. Inhibiting costimulatory activation of T cells: a viable treatment option for rheumatoid arthritis?. Drugs. 2007;67(1):1–9
  147. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot & Ankle International. 2004;25(5):331–335

PII: S1521-6896(08)00049-9

doi: 10.1016/j.bpa.2008.05.005

Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 3 , Pages 585-609 , September 2008

Article Tools

* Image Usage & Resolution